ReviewCureus2026
Sodium-Glucose Cotransporter 2 Inhibitors in Diabetic Nephropathy: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most common causes of end-stage renal disease, which still inflicts a significant clinical and economic burden, is diabetic nephropathy. Even though glycemic and blood pressure management have improved, a considerable proportion of patients progressing to renal failure develop progressive renal dysfunction. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have also proven to be agents with far-reaching renoprotective effects beyond glucose lowering. The present systematic review and meta-analysis synthesizes the existing evidence on the effectiveness and safety of SGLT2 inhibitors in diabetic nephropathy. The review of randomized controlled trials was conducted in line with PRISMA requirements. Twenty studies comprising 131,011 participants were included. SGLT2 inhibitor therapy significantly reduced the risk of composite renal outcomes by 30% (pooled relative risk, 0.70; 95% confidence interval, 0.67 to 0.73; p < 0.001), with minimal heterogeneity across studies (I² = 8.3%). The benefit was consistent across all SGLT2 inhibitor classes (p-value for between-group difference = 0.682), across all stages of chronic kidney disease (CKD) from early to advanced (p = 0.658), and regardless of background renin-angiotensin system (RAS) inhibitor use (p = 0.795). This meta-analysis provides robust evidence that SGLT2 inhibitors confer significant renal protection in patients with diabetic nephropathy, with consistent benefits observed across all drug classes, across all stages of CKD, and irrespective of background RAS inhibitor use. These findings support the incorporation of SGLT2 inhibitors as foundational organ-protective therapy in contemporary clinical practice guidelines for diabetic kidney disease management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.